158 related articles for article (PubMed ID: 25298981)
1. [Medications: dear and expensive?].
Rojahn J
Klin Monbl Augenheilkd; 2014 Feb; 231(2):108-13. PubMed ID: 25298981
[No Abstract] [Full Text] [Related]
2. [Development costs, regulation and audit in the German SHI Drug Sector].
Kamp F; Walter P; Bücheler R
Gesundheitswesen; 2014 Jan; 76(1):7-18. PubMed ID: 24446140
[No Abstract] [Full Text] [Related]
3. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage?
Roman A
Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322
[No Abstract] [Full Text] [Related]
4. Pharmaceuticals and medical devices: business practices. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
[No Abstract] [Full Text] [Related]
5. Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007.
Meron D
Seton Hall Law Rev; 2007; 37(4):929-39. PubMed ID: 18363219
[No Abstract] [Full Text] [Related]
6. [The German law on reorganization of the pharmaceutical market (AMNOG): distinction between innovations and pseudoinnovations].
Doht C
Internist (Berl); 2013 Oct; 54(10):1274. PubMed ID: 24026791
[No Abstract] [Full Text] [Related]
7. FDA chief attacks Canada's drug price controls.
Webster P
Lancet; 2003 Nov; 362(9398):1816. PubMed ID: 14661624
[No Abstract] [Full Text] [Related]
8. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
9. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
10. New drugs and indications in 2012. Sluggish progress, timid measures to protect patients.
Prescrire Int; 2013 Apr; 22(137):105-7. PubMed ID: 23662323
[TBL] [Abstract][Full Text] [Related]
11. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
12. Costing drug development.
Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
[No Abstract] [Full Text] [Related]
13. Paying for drug approvals--who's using whom?
Avorn J
N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
[No Abstract] [Full Text] [Related]
14. Pharmaceuticals and medical devices: business practices.
Steiner DJ
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
[No Abstract] [Full Text] [Related]
15. [Medication prices in Germany--how are they determined?].
Bruhn C
Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
[No Abstract] [Full Text] [Related]
16. Congress, the FDA, and the fair development of new medications for children.
McKinney RE
Pediatrics; 2003 Sep; 112(3 Pt 1):669-70. PubMed ID: 12949299
[No Abstract] [Full Text] [Related]
17. We Can use Market Forces to Moderate Drug Prices.
Miller HI
Mo Med; 2019; 116(6):451-453. PubMed ID: 31911716
[No Abstract] [Full Text] [Related]
18. Regulatory watch: Where do new medicines originate from in the EU?
Lincker H; Ziogas C; Carr M; Porta N; Eichler HG
Nat Rev Drug Discov; 2014 Feb; 13(2):92-3. PubMed ID: 24481298
[No Abstract] [Full Text] [Related]
19. Pharmaceuticals and medical devices: cost savings. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
[No Abstract] [Full Text] [Related]
20. Malfeasance on an industrial scale.
Prescrire Int; 2013 Feb; 22(135):32. PubMed ID: 23444493
[No Abstract] [Full Text] [Related]
[Next] [New Search]